120 related articles for article (PubMed ID: 20085429)
1. Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.
Tommasi C; Ceccherini-Silberstein F; D'Arrigo R; Bellagamba R; Tempestilli M; Dessì C; Santoro MM; Forbici F; Nicastri E; Pucillo LP; Perno CF; Narciso P
Scand J Infect Dis; 2010 Mar; 42(3):237-9. PubMed ID: 20085429
[TBL] [Abstract][Full Text] [Related]
2. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
3. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
4. Management of HIV infection after triple class failure.
Cossarini F; Spagnuolo V; Gianotti N; Carbone A; Lazzarin A; Castagna A
New Microbiol; 2013 Jan; 36(1):23-39. PubMed ID: 23435813
[TBL] [Abstract][Full Text] [Related]
5. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.
Burgos J; Crespo M; Falcó V; Curran A; Imaz A; Domingo P; Podzamczer D; Mateo MG; Van den Eynde E; Villar S; Ribera E
J Antimicrob Chemother; 2012 Jun; 67(6):1453-8. PubMed ID: 22378681
[TBL] [Abstract][Full Text] [Related]
6. Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
Capetti A; Meraviglia P; Landonio S; Sterrantino G; Di Biagio A; Lo Caputo S; Ammassari A; Menzaghi B; De Socio GV; Franzetti M; Soria A; Meschiari M; Sasset L; Pellicanò G; Mazzotta E; Trezzi M; Celesia BM; Melzi S; Carenzi L; Ricci E; Rizzardini G
Int J Antimicrob Agents; 2014 Feb; 43(2):189-94. PubMed ID: 24315315
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
[TBL] [Abstract][Full Text] [Related]
8. Individualized therapy for the treatment-experienced patient.
Walmsley S
AIDS Read; 2003 Jun; 13(6 Suppl):S11-5. PubMed ID: 12838742
[TBL] [Abstract][Full Text] [Related]
9. HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil.
de Souza Cavalcanti J; de Paula Ferreira JL; Vidal JE; de Souza Guimarães PM; Moreira DH; de Macedo Brigido LF;
Int J Antimicrob Agents; 2014 Mar; 43(3):287-91. PubMed ID: 24359837
[TBL] [Abstract][Full Text] [Related]
10. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
[TBL] [Abstract][Full Text] [Related]
11. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Wandeler G; Furrer H; Rauch A
AIDS; 2011 Nov; 25(18):2306-8. PubMed ID: 22067200
[No Abstract] [Full Text] [Related]
12. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
13. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
Bucciardini R; D'Ettorre G; Baroncelli S; Ceccarelli G; Parruti G; Weimer LE; Fragola V; Galluzzo CM; Pirillo MF; Lucattini S; Bellagamba R; Francisci D; Ladisa N; Degli Antoni A; Guaraldi G; Manconi PE; Vullo V; Preziosi R; Cirioni O; Verucchi G; Floridia M;
Int J STD AIDS; 2012 Jul; 23(7):459-63. PubMed ID: 22843997
[TBL] [Abstract][Full Text] [Related]
14. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
15. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.
Llibre JM; Schapiro JM; Clotet B
Clin Infect Dis; 2010 Mar; 50(6):872-81. PubMed ID: 20158400
[TBL] [Abstract][Full Text] [Related]
20. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
